Across TCGA pan-cancer cohorts, DCAF15 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated DCAF15 data layer compared with 27 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher DCAF15 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DCAF15 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
HNSC, PRAD, and SKCM are the cancer types where DCAF15 Mutation most reproducibly stratifies survival.